Protara Therapeutics, Inc.
5.20+0.11 (+2.16%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · TARA · USD
Key Stats
Market Cap
200.63MP/E (TTM)
-Basic EPS (TTM)
-1.56Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Protara Therapeutics posted a Q2 net loss of $15.0M, up 57% y/y from $9.5M, driven by R&D expenses climbing 69% to $10.8M on NMIBC and IV Choline Chloride trial ramps, while G&A rose 36% to $5.8M. Operating loss widened to $16.6M from $10.7M y/y, offset by $1.6M in interest income, yielding diluted EPS of -$0.35 on 42.3M shares—better than last year's -$0.45 on 21.2M shares, with no anti-dilution flagged. Cash burned $27.0M in operations, leaving $145.6M in unrestricted cash and securities at quarter-end, down from $170.3M year-start, with no debt. Cash is solid for trials. Yet clinical setbacks could stall progress.
8-K
Q2 loss widens on trial costs
Protara Therapeutics reported a Q2 2025 net loss of $15.0 million, up from $9.5 million last year, driven by ramped-up R&D spending on TARA-002 and IV Choline Chloride trials. Cash reserves stand at $145.6 million, funding operations into mid-2027. Pipeline advances include interim ADVANCED-2 data in 1Q 2026 and THRIVE-3 dosing in 3Q 2025. Expenses surged, yet runway holds firm.
8-K
Annual meeting elects directors
Protara Therapeutics held its annual stockholder meeting on June 11, 2025, electing Luke Beshar, Roger Garceau, M.D., and Gregory Sargen as Class II directors until 2028, with strong support for Garceau and Sargen but notable withheld votes for Beshar. Stockholders ratified Ernst & Young as auditors for 2025, approved executive compensation on an advisory basis, and passed the amendment to the 2024 Equity Incentive Plan. This governance refresh signals continuity. Yet, withheld votes highlight scrutiny on board composition.
10-Q
Q1 FY2025 results
Protara Therapeutics reported a Q1 2025 net loss of $11.9 million, up 7% year-over-year from $11.1 million, driven by higher R&D expenses of $9.1 million (up 18% y/y) tied to TARA-002 in NMIBC and IV Choline Chloride programs, while G&A rose 21% to $5.0 million. Operating loss widened to $14.1 million (up 19% y/y), but other income jumped to $2.2 million from $0.8 million, thanks to interest on larger balances. Diluted EPS improved to $(0.29) from $(0.97), reflecting a tripling of shares to 40.7 million post-2024 offerings; no anti-dilution flagged. Cash burned $14.7 million in operations with no capex, leaving $157.5 million in unrestricted cash and securities—enough for at least 12 months. Cash dipped 44% q/q to $91.5 million after investing $58.4 million in securities. No debt. Yet clinical momentum builds: interim ADVANCED-2 data showed 100% complete response in small BCG-unresponsive NMIBC cohort. Competition in crowded bladder cancer space looms large.
8-K
Q1 loss widens on trial advances
Protara Therapeutics reported Q1 2025 net loss of $11.9 million, up from $11.1 million last year, driven by higher R&D spending on TARA-002 and IV Choline Chloride trials, while ending with $158 million in cash to fund operations into 2027. Positive interim ADVANCED-2 data showed 100% complete response in small BCG-unresponsive NMIBC cohort, with full interim results from 25 patients due by year-end. Leadership bolstered by new CMO and HR head. Cash burn quickens, yet runway holds firm.
ATOS
Atossa Therapeutics, Inc.
0.88-0.06
ATRA
Atara Biotherapeutics, Inc.
14.06-1.15
BCAX
Bicara Therapeutics Inc.
15.88-1.21
FATE
Fate Therapeutics, Inc.
1.34-0.15
PPCB
Propanc Biopharma, Inc.
1.31-0.11
PROK
ProKidney Corp.
3.10+0.06
PTIX
Protagenic Therapeutics, Inc.
2.58-0.18
PVCT
Provectus Biopharmaceuticals, I
0.07+0.00
SVRA
Savara, Inc.
4.34-0.07
TVRD
Tvardi Therapeutics, Inc.
4.78+0.06